|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
ER/PR/HER2, FISH, Paraffin Block [70133X]
Test Code70133
CPT Codes
88360 (x2), 88377
Preferred Specimen
Formalin-fixed, paraffin-embedded tumor tissue block submitted in an IHC Specimen Transport kit
Minimum Volume
1 block
Instructions
Invasive primary or metastatic breast or gastric cancer formalin-fixed, paraffin-embedded tissue or charged/+slides from formalin-fixed, paraffin-embedded tissue. Specimen MUST be fixed in 10% neutral buffered formalin. Cold ischemic time of less than 1 hour and fixation between 6 and 72 hours is recommended.
Pathology report must accompany paraffin block or slides.
Information required in this report includes: Physician identification, specimen identifiers (case and block number), specimen site and type, collection date, collection time, tissue processing used (routine or microwave), cold ischemic time, type of fixative, duration of fixation, pathologic diagnosis, and IHC score, if performed elsewhere. Ship at room temperature. Do not freeze. Do not reject.
Pathology report must accompany paraffin block or slides.
Information required in this report includes: Physician identification, specimen identifiers (case and block number), specimen site and type, collection date, collection time, tissue processing used (routine or microwave), cold ischemic time, type of fixative, duration of fixation, pathologic diagnosis, and IHC score, if performed elsewhere. Ship at room temperature. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Methodology
Fluorescence in situ Hybridization (FISH) • Immunohistochemistry (IHC)
Setup Schedule
Set up: Mon-Fri; Report available: 6 days
Reference Range
See Laboratory Report
Clinical Significance
Estrogen and progesterone receptor assays are routinely performed on breast carcinomas to assess responsiveness to endocrine therapy and prognosis. HER-2 is associated with cellular proliferation activity. Over-expression is observed in 25-30% of women with breast cancer. These patients are potential candidates for monoclonal therapy.
